FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1371-1375 October 24, 2002 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Editorial by Drazen, J. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The relationships between academic institutions and private companies are strengthening. The decision of several large pharmaceutical companies, and many biotechnology companies, to build major new laboratories near U.S., European, and Asian universities is just one example of the growing commercial value of academic innovation in biomedicine and the talent that produces it. Individual faculty members and universities in the United States and other countries have increasingly strong financial and nonfinancial incentives to start new companies and to participate directly in the development of drugs, devices, and diagnostic tests.¹

Many negative implications of this trend have been recognized. Articles in the . . . [Full Text of this Article]

The Forces Changing Biomedical Research

Conflicting Expectations

Patients and Their Families

Large and Small Companies (and Their Investors)

The Press, Legislators, and Regulators

Choices and Implications

Choice 1: Should Commercial Ties Be Encouraged?

            Issues

            Recommendation

Choice 2: Should Industry Ties Be Managed within the Academic Medical Center?

            Issues

            Recommendation

Choice 3: Should Faculty Be Identified with Companies?

            Issues

            Recommendation

Choice 4: Should Restrictions on Clinical Research and Basic Reseach Be Treated Differently?

            Issues

            Recommendation

Choice 5: Should Devices Be Treated as a Special Case?

            Issues

            Recommendation

Choice 6: How Is the Proper Balance between Commercially Sponsored Research and Government or Foundation Research to Be Achieved?

            Issues

            Recommendation

Choice 7: How Should Institutional Conflicts of Interest Be Managed?

            Issues

            Recommendation

Conclusions

Related Letters:

Industrial Collaboration
Rosoff P. M., Moses H. III, Braunwald E., Martin J. B.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:863-864, Feb 27, 2003. Correspondence

This article has been cited by other articles:

• Camilleri, M., Gamble, G. L., Kopecky, S. L., Wood, M. B., Hockema, M. L. (2005). Principles and Process in the Development of the Mayo Clinic's Individual and Institutional Conflict of Interest Policy. Mayo Clin Proc. 80: 1340-1346 [Abstract]  
• Mello, M. M., Clarridge, B. R., Studdert, D. M. (2005). Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry. NEJM 352: 2202-2210 [Abstract] [Full Text]  
• Ryan, T. J., DeSanctis, R. W. (2005). Dr Jerome Kassirer's Book On The Take: How Medicine's Complicity With Big Business Can Endanger Your Health: Worthy of Comment. Circulation 111: 2552-2554 [Full Text]  
• Rawlins, M. D (2005). Neglected diseases. BMJ 330: 376-377 [Full Text]  
• Studdert, D. M., Mello, M. M., Brennan, T. A. (2004). Financial Conflicts of Interest in Physicians' Relationships with the Pharmaceutical Industry -- Self-Regulation in the Shadow of Federal Prosecution. NEJM 351: 1891-1900 [Full Text]  
• Califf, R. M., Nissen, S. E., DeMaria, A. N., Ohman, E. M., Pitt, B., Willerson, J. T., Bilheimer, D. W., Cohn, J. N., Feigal, D. W. Jr, Hampson, L., Lorell, B. H., Pepine, C. J., Popp, R. L. (2004). Task force 2: Investigator participation in clinical research. J Am Coll Cardiol 44: 1729-1736 [Full Text]  
• Califf, R. M., Nissen, S. E., DeMaria, A. N., Ohman, E. M., Pitt, B., Willerson, J. T., Bilheimer, D. W., Cohn, J. N., Feigal, D. W. Jr, Hampson, L., Lorell, B. H., Pepine, C. J., Popp, R. L. (2004). Task Force 2: Investigator Participation in Clinical Research. Circulation 110: 2517-2524 [Full Text]  
• Parascandola, M (2003). Hazardous effects of tobacco industry funding. J. Epidemiol. Community Health 57: 548-549 [Full Text]  
• Chopra, S. S. (2003). Industry Funding of Clinical Trials: Benefit or Bias?. JAMA 290: 113-114 [Full Text]  
• Baird, P. (2003). Getting it right: industry sponsorship and medical research. CMAJ 168: 1267-1269 [Full Text]  
• Rosoff, P. M., Moses, H. III, Braunwald, E., Martin, J. B. (2003). Industrial Collaboration. NEJM 348: 863-864 [Full Text]  
• (2002). The controlling interests of research. CMAJ 167: 1221-1221 [Full Text]  
• (2002). Les interets qui controlent la recherche. CMAJ 167: 1223-1223 [Full Text]  
• Drazen, J. M. (2002). Institutions, Contracts, and Academic Freedom. NEJM 347: 1362-1363 [Full Text]